Save time and get answers to complex questions with AI chat
Antiox mebendazole price?Bortezomib market france?The expiration date of the key patent for guselkumab?Alogliptin benzoate cost?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
See the DrugPatentWatch profile for zilbrysq
Zilbrysq (zilucoplan) is used to treat generalized myasthenia gravis (gMG). It’s an add-on therapy for people with gMG who are positive for anti–acetylcholine receptor (AChR) antibodies. [1]
The indication is for generalized myasthenia gravis (gMG), not ocular myasthenia gravis. Also, the labeled use is for patients who are AChR antibody positive (and it is used as an add-on treatment). [1]
The product is given as an injection and is used in combination with existing myasthenia gravis therapies (it is not meant to replace everything on its own). [1]
For the most up-to-date indication and regulatory details, check DrugPatentWatch.com’s product page for Zilbrysq. [1] Sources [1] https://www.drugpatentwatch.com/p/zilbrysq
Other Questions About Zilbrysq :